EUVIMEDEUVIMED entdecken
Delphi-StudieOpen Access

Redefining Cancer Research Priorities in Low- and Middle-Income Countries in the Post–COVID-19 Global Context: A Modified Delphi Consensus Process

Louis Fox iD, Aida Santaolalla, Jasmine Handford iD, Richard Sullivan iD, Julie Torode iD, Verna Vanderpuye iD, C S Pramesh iD, Layth Mula-Hussain iD, Shaymaa AlWaheidi iD, Lydia E Makaroff iD, Ranjit Kaur, Clara Mackay und 2 weitere

JCO Global Oncology · 2023-08 · (9)

DOI: 10.1200/go.23.00111 ↗

Kurz gefasst

Delphi-Studie in der Zeitschrift JCO Global Oncology, 2023-08. Verfasst von Louis Fox und 13 weiteren Autor:innen. Beteiligte Einrichtung: Translational Oncology and Urology Research (TOUR), Centre for Cancer, Society and Public Health, King's College London, London, United Kingdom. Hauptthemen laut MEDLINE: COVID-19, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The post–COVID-19 funding landscape for cancer research globally has become increasingly challenging, particularly in resource-challenged regions (RCRs) lacking strong research ecosystems. We aimed to produce a list of priority areas for cancer research in countries with limited resources, informed by researchers and patients. METHODS Cancer experts in lower-resource health care systems (as defined by the World Bank as low- and middle-income countries; N = 151) were contacted to participate in a modified consensus-seeking Delphi survey, comprising two rounds. In round 1, participants (n = 69) rated predetermined areas of potential research priority (ARPs) for importance and suggested missing ARPs. In round 2, the same participants (n = 49) rated an integrated list of predetermined and suggested ARPs from round 1, then undertook a forced choice priority ranking exercise. Composite voting scores ( T-scores) were used to rank the ARPs. Importance ratings were summarized descriptively. Findings were discussed with international patient advocacy organization representatives. RESULTS The top ARP was research into strategies adapting guidelines or treatment strategies in line with available resources (particularly systemic therapy) ( T = 83). Others included cancer registries ( T = 62); prevention ( T = 52); end-of-life care ( T = 53); and value-based and affordable care ( T = 51). The top COVID-19/cancer ARP was strategies to incorporate what has been learned during the pandemic that can be maintained posteriorly ( T = 36). Others included treatment schedule interruption ( T = 24); cost-effective reduction of COVID-19 morbidity/mortality ( T = 19); and pandemic preparedness ( T = 18). CONCLUSION Areas of strategic priority favored by cancer researchers in RCRs are related to adaptive treatment guidelines; sustainable implementation of cancer registries; prevention strategies; value-based and affordable cancer care; investments in research capacity building; epidemiologic work on local risk factors for cancer; and combatting inequities of prevention and care access.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19NeoplasmsHumansDelphi TechniqueDeveloping CountriesEcosystemResearch

Autor:innen und Institutionen

  • Translational Oncology and Urology Research (TOUR), Centre for Cancer, Society and Public Health, King's College London, London, United Kingdom.
  • Global Oncology Group, Centre for Cancer, Society and Public Health, King's College London, London, United Kingdom.
  • National Centre for Radiotherapy, Oncology and Nuclear Medicine, Korle Bu Teaching Hospital, Accra, Ghana.
  • Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
  • Sultan Qaboos Comprehensive Cancer Care and Research Centre, Muscat, Oman.
  • World Bladder Cancer Patient Coalition, Brussels, Belgium.

ORCID-Profile: Louis Fox, Jasmine Handford, Richard Sullivan, Julie Torode, Verna Vanderpuye, C S Pramesh, Layth Mula-Hussain, Shaymaa AlWaheidi, Lydia E Makaroff, Deborah Mukherji, Mieke Van Hemelrijck

Zitieren

APA

Fox, L., Santaolalla, A., Handford, J., Sullivan, R., Torode, J., Vanderpuye, V., Pramesh, C. S., Mula-Hussain, L., AlWaheidi, S., Makaroff, L. E., Kaur, R., Mackay, C., Mukherji, D., & Van Hemelrijck, M. (2023). Redefining Cancer Research Priorities in Low- and Middle-Income Countries in the Post–COVID-19 Global Context: A Modified Delphi Consensus Process. JCO Global Oncology. https://doi.org/10.1200/go.23.00111

Vancouver

Fox L, Santaolalla A, Handford J, Sullivan R, Torode J, Vanderpuye V, et al. Redefining Cancer Research Priorities in Low- and Middle-Income Countries in the Post–COVID-19 Global Context: A Modified Delphi Consensus Process. JCO Global Oncology. 2023. doi:10.1200/go.23.00111

BibTeX
@article{Fox2023,
  author = {Fox, Louis and Santaolalla, Aida and Handford, Jasmine and Sullivan, Richard and Torode, Julie and Vanderpuye, Verna and Pramesh, C S and Mula-Hussain, Layth and AlWaheidi, Shaymaa and Makaroff, Lydia E and Kaur, Ranjit and Mackay, Clara and Mukherji, Deborah and Van Hemelrijck, Mieke},
  title = {Redefining Cancer Research Priorities in Low- and Middle-Income Countries in the Post–COVID-19 Global Context: A Modified Delphi Consensus Process},
  journal = {JCO Global Oncology},
  year = {2023},
  number = {9},
  doi = {10.1200/go.23.00111}
}
Kostenlos starten →